Bernstein Projects $195 Billion Growth for India's Biopharma Sector in 'Innovation Power Decade'
Bernstein sees 'Innovation Power Decade' for India's healthcare sector
Image: Asianet Newsable
Bernstein has launched coverage of India's healthcare sector, predicting a significant growth in the biopharma industry to $195 billion over the next decade. Key drivers include niche therapies and six innovation areas expected to contribute $70-75 billion. The report also highlights stock recommendations, emphasizing the potential of AI in enhancing profitability.
- 01Bernstein identifies six innovation areas, including drug-device combinations and RNA therapies, as key contributors to growth.
- 02Zydus Lifesciences is rated as the top stock pick, followed by Lupin and Sun Pharma, all with an Outperform rating.
- 03The report anticipates a $400 billion opportunity from new healthcare modalities that could add 100 million patients annually.
- 04AI adoption is expected to enhance profit margins by three to four percentage points, with R&D driving most of this increase.
- 05Bernstein notes that Indian biopharma is on a path to becoming a global leader in innovative medicine production.
Advertisement
In-Article Ad
Bernstein has initiated coverage on India's healthcare sector, dubbing the upcoming decade as an 'Innovation Power Decade.' The firm forecasts that the biopharma industry will grow fourfold to $195 billion by 2033, driven by advancements in niche therapies and six key innovation categories, which are expected to add $70-75 billion to the industry's size. The report highlights that Zydus Lifesciences is the top stock pick, followed by Lupin and Sun Pharma, all rated Outperform. Bernstein's analysis suggests that the healthcare sector will experience a significant transformation driven by three waves: increased demand for innovative healthcare solutions, greater health infrastructure in emerging economies, and a cultural shift towards quality and image consciousness. Additionally, the adoption of artificial intelligence (AI) is projected to enhance profitability, potentially increasing profit margins by three to four percentage points. Bernstein's outlook indicates that Indian biopharma is poised to lead in global innovation, supported by a robust network of future-ready manufacturing plants.
Advertisement
In-Article Ad
The growth of the biopharma sector could lead to increased job opportunities and advancements in healthcare access for the Indian population.
Advertisement
In-Article Ad
Reader Poll
How optimistic are you about the future of India's biopharma sector?
Connecting to poll...
More about Bernstein
NVIDIA Maintains AI Dominance Despite Market Pressures, Analysts Say
Benzinga • May 22, 2026
Jefferies incrementa su precio objetivo para Nvidia a 300 dólares impulsado por el crecimiento en IA
Investing • May 21, 2026
Bernstein ajuste ses prévisions pour Lam Research et KLA Corp. après une révision à la hausse des dépenses en équipements
Investing French • May 20, 2026
Read the original article
Visit the source for the complete story.